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Abstract
Background: Diosgenin, a steroidal saponin obtained from fenugreek (Trigonella foenum graecum), was found to exert anti-
carcinogenic properties, such as inhibiting proliferation and inducing apoptosis in a variety of tumor cells. However, the
effect of diosgenin on cancer metastasis remains unclear. The aim of the study is to examine the effect of diosgenin on
migration and invasion in human prostate cancer PC-3 cells.
Methods and Principal Findings: Diosgenin inhibited proliferation of PC-3 cells in a dose-dependent manner. When treated
with non-toxic doses of diosgenin, cell migration and invasion were markedly suppressed by in vitro wound healing assay
and Boyden chamber invasion assay, respectively. Furthermore, diosgenin reduced the activities of matrix metalloprotei-
nase-2 (MMP-2) and MMP-9 by gelatin zymography assay. The mRNA level of MMP-2, -9, -7 and extracellular inducer of
matrix metalloproteinase (EMMPRIN) were also suppressed while tissue inhibitor of metalloproteinase-2 (TIMP-2) was
increased by diosgenin. In addition, diosgenin abolished the expression of vascular endothelial growth factor (VEGF) in PC-3
cells and tube formation of endothelial cells. Our immunoblotting assays indicated that diosgenin potently suppressed the
phosphorylation of phosphatidylinositide-3 kinase (PI3K), Akt, extracellular signal regulating kinase (ERK) and c-Jun N-
terminal kinase (JNK). In addition, diosgenin significantly decreased the nuclear level of nuclear factor kappa B (NF-kB),
suggesting that diosgenin inhibited NF-kB activity.
Conclusion/Significance: The results suggested that diosgenin inhibited migration and invasion of PC-3 cells by reducing
MMPs expression. It also inhibited ERK, JNK and PI3K/Akt signaling pathways as well as NF-kB activity. These findings reveal
new therapeutic potential for diosgenin in anti-metastatic therapy.
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Introduction
Diosgenin is a naturally occurring steroidal saponin present in a
variety of plants including fenugreek (Trigonella foenum graecum)a n d
roots of wild yam (Dioscorea villosa) [1]. Diosgenin has been used in
traditional medicine as an antihypercholesterolemia, antihypertria-
cylglycerolemia, antidiabetes and antihyperglycemia agent [1,2,3,4].
Several reports have showedthatdiosgenin inhibits proliferation and
induces apoptosis in a wide variety of tumor cells of human colon
[5], osteosarcoma [6], leukemia [7], erythroleukemia [8], breast [9],
and liver [10]. The anti-cancer effect of diosgenin has been
demonstrated through cell cycle arrest [7,11], activation of p53
and caspase-3 [5,7,8,12]. In addition, diosgenin inhibits NF-kB
activity and NF-kB-regulated gene expression and subsequently
reducing proliferation, invasion and osteoclastogenesis [6,13].
Diosgenin also abolishes cyclooxygenase-2 [11] and lipoxygenase
[14],whichareimplicatedincarcinogenesisandasimportanttargets
for cancer chemoprevention and therapy. Therefore, diosgenin may
possess the cancer chemotherapeutic potential and its activity
involves multiple cellular and molecular targets.
Prostate cancer is one of the most commonly diagnosed tumors
in men and the second leading cause of cancer mortality in the
United States [15]. Although prostate cancer at the early stage can
be treated with surgery and androgen-deprivation therapy, it
eventually progress to more malignant, metastasis, and hormone
refractory prostate cancer (HRPC), for which there is no curative
therapy [16,17]. Thus, development of innovative therapies for the
treatment of prostate cancer is needed. Because advanced prostate
cancer cell with highly invasive potential result in high morbidity
and mortality rates, inhibition of invasion and metastasis might be
a good approach for treatment of HRPC.
Cancer metastasis is a highly coordinated step-wise process that
includes detachment of cells from the primary tumor, local
proteolysis of the extracellular matrix (ECM), penetration through
the basement membrane of capillary and lymphatic vessels,
intravasation, and then invasion into new tissue and growth
[18,19]. The process of metastasis is promoted by expressing and
secreting various proteolytic enzymes that can degrade most ECM
components. Matrix metalloproteinases (MMPs), a family of Zn-
dependent endopeptidases, are the major proteases participating in
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Among the MMPs, MMP-2 and MMP-9 are key enzymes for
degrading type IV collagen and contribute to the process of
metastasis[21,22].MMP-2and MMP-9arealsocapableofcleaving
type I collagen [23,24], the major component forming a lattice
structure in stroma [25]. The activation of these enzymes have been
associated with increasing tumor metastasis, suggesting an central
functional role for these proteases in the metastatic process [26].
Proteolytic degradation of stromal microenvironment plays a
critical role in promoting invasion. To acquire detailed information
on cancer cell invasion on the stroma, type I collagen is used in
Boyden chamber invasion assay in the present study.
In addition, proteolytic degradation of ECM in tumor metastasis
can be regulated by other proteins such as extracellular inducer of
matrix metalloproteinase (EMMPRIN) and tissue inhibitor of
metalloproteinases (TIMPs). EMMPRIN is a multifunctional glycoprotein that can modify the tumor microenvironment by
activating proteinases, inducing angiogenic factors in tumor and
stromal cells. EMMPRIN is able to regulate MMPs and be involved
in the invasion and metastasis processesof prostate cancer cells [27].
The activities of most MMPs are regulated by TIMPs. The balance
between MMP and TIMP levels is an important determinant of the
net proteolytic activity [28].
Mitogen-activated protein kinase (MAPK) pathway has been
known to participate in numerous signaling cascades that play
important regulatory roles in cell growth, apoptosis, differentia-
tion, and metastasis [29]. The diverse MAPK members are
activated in response to various extracellular stimuli and have
distinct downstream targets, thus stimulating cell migration,
proteinase-induction, and angiogenesis, events that are essential
for metastasis [30]. Extracellular signal regulating kinase (ERK1/
2) and c-Jun N-terminal kinase (JNK), two major mammalian
MAP kinases, have been implicated in cell migration and
proteinase-induction, events that are essential for metastasis [30].
ERK1/2 and JNK play a central role in regulating the expression
of MMPs [20]. Inhibition of the MAPK pathway might have the
potential to prevent angiogenesis, proliferation, invasion, and
metastasis for a wide range of tumors [31,32,33]. Metastasis is also
regulated by the PI3K/Akt signaling pathway, which is involved in
many cellular processes including cell survival, cell adhesion and
Figure 1. Effect of diosgenin on viabilities of PC-3 cell. Cells were
treated with various concentrations of diosgenin for 24 h and 48 h. Cell
viability is presented as mean 6 S.D. of four independent experiments.
***p,0.001 compared with the untreated control.
doi:10.1371/journal.pone.0020164.g001
Figure 2. Effect of diosgenin on migration of PC-3 cells. Cell
monolayers were scraped by a sterile micropipette tip and the cells
were treated with various concentrations of diosgenin for 24 h. (A) Cells
migrated to the wounded region were photographed (1006 magnifi-
cation). (B) The wound area of the cell cultures were quantified in four
fields in each treatment, and data were calculated from three
independent experiments. Data are presented as as mean 6 S.D. of
three independent experiments. *p,0.05, **p,0.01, compared with the
untreated control.
doi:10.1371/journal.pone.0020164.g002
Table 1. Primer pairs used in Quantitative Real-Time PCR.
Gene Sequence (59-39)
Amplicon
(bp)
MMP-2-F CTTCCAAGTCTGGAGCGATGT 119
MMP-2-R TACCGTCAAAGGGGTATCCAT
MMP-9-F GGGACGCAGACATCGTCATC 139
MMP-9-R TCGTCATCGTCGAAATGGGC
MMP-7-F GGAGGAGATGCTCACTTCGAT 118
MMP-7-R AGGAATGTCCCATACCCAAAGA
EMMPRIN-F CTACACATTGAGAACCTGAACAT 170
EMMPRIN-R TTCTCGTAGATGAAGATGATGGT
TIMP-1-F CTTCTGCAATTCCGACCTCGT 127
TIMP-1-R CCCTAAGGCTTGGAACCCTTT
TIMP-2-F AAGCGGTCAGTGAGAAGGAAG 153
TIMP-2-R CACACACTACCGAGGAGGG
b-actin-F CATGTACGTTGCTATCCAGGC 250
b-actin-R CTCCTTAATGTCACGCACGAT
doi:10.1371/journal.pone.0020164.t001
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pathways may have the potential to prevent cancer cell
proliferation, invasion, and metastasis [31,33]. In addition,
PI3K/Akt and MAPK signaling pathways play a central role in
regulating the expression of MMPs by transcriptional factors,
including NF-kB [34,36,37]. NF-kB is kept in an inactive form in
the cytoplasm by inhibitory proteins called inhibitors of kB( I kB).
In response to an activation signal, NF-kB is released from IkBa
and translocates from the cytoplasm to the nucleus, where it binds
to cognate sequences in the promoter region of a number of target
genes and subsequently facilitates cell proliferation, angiogenesis,
and metastasis. Thus, blocking PI3K/Akt and MAPK pathways as
well as NF-kB provide potential targets for tumor therapeutic
strategies.
Although diosgenin is implicated as a novel multitarget-based
chemopreventive agent against several cancer cells, the role of
diosgenin against tumor metastasis and angiogenesis is still
unclear. The objective of this work is to examine the inhibitory
effects and molecular mechanisms of diosgenin on metastasis.
Since human prostate cancer PC-3 cell exhibits highly invasive
and metastatic activity and has been used for investigating the
biochemical changes in advanced prostatic cancer cells and in
assessing their response to chemotherapeutic agents [38], PC-3 cell
was used for the present experiments.
Materials and Methods
Reagents and Cell Culture
Diosgenin, dimethyl sulfoxide (DMSO), Tris-HCl, EDTA, SDS,
phenylmethylsulfonyl fluoride (PMSF), Nonidet P-40, deoxycholic
acid and sodium orthovanadate, were purchased from Sigma-
Aldrich (St. Louis, MO). Protein assay kit was obtained from Bio-
Rad Labs (Hercules, CA). Powdered Dulbecco’s modified Eagle’s
medium (DMEM) was purchased from Gibco/BRL (Gaithers-
burg, MD). Total RNA extraction kit and PCR kit were from
Viogene (Sunnyvale, CA). Antibodies against ERK, JNK, Akt,
NF-kB (p65), C23 and phosphorylated proteins were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against PI3K and phosphorylated PI3K were purchased from Cell
Signaling Technology (Danvers, MA). Human prostate cancer cell
lines PC-3 and was obtained from BCRC (Food Industry Research
and Development Institute, Taiwan). Cells were maintained in
DMEM supplemented with 10% fetal calf serum, 100 U/ml of
penicillin and 100 mg/ml streptomycin, and incubated in a 5%
CO2 humidified incubator at 37uC. Human umbilical vein
endothelial cell (HUVEC), kindly provided from Dr. Hua-Lin
Wu [39], was isolated from human umbilical cord veins as
previously described [39], and cultured on 0.1% gelatin-coated
dishes and maintained in M199 medium supplemented with 16%
FBS, endothelial cell growth supplement and heparin sulfate
(Upstate Biotechnology). HUVECs between passages 2 and 6 were
used in all experiments. For diosgenin treatment, diosgenin was
dissolved in ethanol and diluted with culture medium (the final
concentration of ethanol was less than 0.2%).
Cell Viability Assay
The assay was performed as described previously [40]. Briefly,
cells were seeded in a 96-well plate and treated with diosgenin in
triplicate. After 24 and 48 hrs of incubation, the medium was
replaced with fresh medium containing 0.5 mg/ml MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. After 4
hrs, the supernatants were removed and the resulting MTT
formazan was solubilized in DMSO and measured spectrophoto-
metrically at 570 nm.
Wound Healing Migration Assay
The assay was performed as described previously [41]. PC-3
cells were plated in a 12-well plate and grew to confluence. The
monolayer culture was then scrape-wounded with a sterile
micropipette tip to create a denuded zone (gap) of constant width.
After removing the cellular debris with PBS, cells were exposed to
various concentrations of diosgenin after 24 hrs. PC-3 cells
migrated to the wounded region were observed by Olympus CK-2
inverted microscope and photographed (1006magnification). The
wound area was measured by the program Image J (http://rsb.
info.nih.gov/ij/). The percentage of wound closure was estimated
by the following equation: Wound closure % = [1-(wound area at
Tt/wound area at T0) 6100%, where Tt is the time after
wounding and T0 is the time immediately after wounding.
Figure 3. Effect of diosgenin on invasion of PC-3 cells. Cells were
treated with various concentrations of diosgenin for 24 h and cell
invasion assay was performed. (A) The invaded cells were photo-
graphed (2006magnification). (B) The invaded PC-3 cells were counted
in five random fields in each treatment, and data were calculated from
three independent experiments. Data are presented as mean 6 S.D. of
three independent experiments. *p,0.05, **p,0.01, compared with the
untreated control.
doi:10.1371/journal.pone.0020164.g003
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Boyden chamber invasion assay was carried out as previously
[41]. Briefly, the polycarbonate filter (8 mm pore) was pre-coated
with type-I collagen (10 mg/ml). After treated with diosgenin for
24 hrs, cells (1610
4 cells/well) were added to the upper chamber
in serum-free medium. The complete medium (containing 10%
FBS) was applied to the lower chamber as chemoattractant. The
chamber was incubated for 6 hrs at 37 uC. At the end of
incubation, the cells in the upper surface of the membrane were
carefully removed with a cotton swab and cells that invaded to the
lower surface of the membrane were fixed with methanol and
stained with 5% Giemsa solution. The invaded cells on the lower
surface of the membrane filter were scored from five random fields
under microscopy (2006magnification).
Tube Formation Determination
The tube formation assay was performed as described. Briefly, a
15-well m-Slides (ibidi, Germany) was coated with 10 ml of Matrigel
which was allowed to solidify at 37 uC. To evaluate the effect of
diosgenin, PC-3 cells were treated with various concentrations of
diosgenin for 24 hrs and the conditioned medium were collected
and subjected to tube formation assay. HUVEC were seeded on the
Matrigel and cultured in conditioned medium of PC-3 cell for 6 hrs.
The enclosed networks of complete tubes were counted and
photographedunderaninverted microscope.Thetubularlengthsof
the cells were measured using the program Image J.
RNA Extraction and Reverse Transcription PCR and
Quantitative Real-Time PCR
Total RNA was extraction using total RNA extraction kit
according to the manufacturer’s instructions. Total RNA (1 mg)
from each sample was subject to reverse transcription with
oligo(dT) primers by PCR kit according to manufacturer’s
instruction. The synthesized cDNA was used for PCR amplifica-
tion with the following primers [41]: MMP-9, 59-gcacgacgtcttc-
cagtacc-39 (For), 59-tcaactcactccgggaactc-39 (Rev); MMP-2, 59-
ggactatgaccgggataagaaatatg-39(For),59-gggcaccttctgaatttcca-39(Rev);
b-actin: 59-TGTTACCAACTGGGACGACA-39 (For), 59-GGG-
GTGTTGAAGGTCTCAAA-39 (Rev). cDNAs were amplified
for 35 cycles and each PCR reaction condition was as follows:
preparation step at 94uC for 5 min, denaturing step at 94uC for
30 sec, annealing step at 56uC for 30 sec, and polymerization
step at 72uC for 30 sec. PCR products were analyzed by
agarose gel electrophoresis. The mRNA expressions of MMP-2,
-9, -7, EMMPRIN and TIMP-1,-2 were determined by
quantitative real-time PCR which is conducted in StepOne
system (Applied Biosystem, Foster City, CA, USA). Briefly, each
amplification mixture (50 ml) contains 10 ng cDNA and 25 ml
SYBR Green PCR Master Mix (Applied Biosystems). PCR
conditions were as follows: 95 uC for 2 min, 40 cycles at 95 uC
for 15 s and 60 uC for 45 s. The primer sequences for b-actin,
MMP-2, MMP-9, MMP-7, EMMPRIN, TIMP-1, TIMP-2 and
vascular endothelial growth factor (VEGF) were deduced from
PrimerBank and listed in Table 1. PCR results were derived
using the comparative CT method.
Analysis of MMP-2 and MMP-9 Activities by Gelatin
Zymography
The activities of MMP-2 and MMP-9 were assayed by gelatin
zymography as described previously [41]. Briefly, subconfluent
PC-3 cells were incubated with serum-free medium with various
concentrations of diosgenin for 24 hrs. The conditioned medium
Figure 4. Effect of diosgenin on the activities and expressions of MMP-2/9/7, EMMPRIN and TIMP-1/2 in PC-3 cells. (A) PC-3 cells were
treated with various concentrations of diosgenin for 24 h and the activities of MMP-9 and MMP-2 were determined by gelatin zymography. The
expressions of MMP-9 and MMP-2 mRNA (B) and protein (C) were analyzed by RT-PCR and Western blotting, respectively. b-actin was used as an
internal control. (D) The levels of MMP-2, -9, -7, EMMPRIN and TIMP-1,-2 mRNA were expressed as mean 6 S.D. of three independent experiments.
*p,0.05, **p,0.01, compared with the untreated control.
doi:10.1371/journal.pone.0020164.g004
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gation. The sample (20 mg) was mixed with loading buffer and
subjected to 10% SDS-polyacrylamide gel containing 0.1%
gelatin. Electrophoresis was performed at 100 V for 3 h at 4uC.
Gels were then washed with washing buffer (2.5% Triton X-100 in
dd H2O) at room temperature to remove SDS, followed by
incubation at 37uC in reaction buffer (40 mM Tris-HCl, pH 8.0,
10 mM CaCl2, 0.02% NaN3). After 16 h, the gels were stained
with Comassie blue R-250 (0.125% Comassie blue R-250, 50%
methanol, 10% acetic acid) for 1 h and destained with destaining
solution (20% methanol, 10% acetic acid, 70% ddH2O) until the
clear bands were visualized.
Nuclear Protein Extraction
The nuclear proteins were prepared as previously described
[41]. Briefly, cells were washed with ice-cold PBS, centrifuged, and
resuspended in hypotonic buffer (10 mM HEPES, pH 7.9, 1.5
mM MgCl2, 10 mM KCl, 0.05% NP-40, 0.5 mM DTT and 0.5
mM PMSF). The nuclei were centrifuged for 10 min at 3000 rpm
at 4uC. The pellet was then resuspended in nuclear extract buffer
(20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2
mM EDTA, 0.5 mM DTT, 0.5 mM PMSF and 25% glycerol) and
incubated for 30 min on ice. After another centrifugation at
14,000 rpm for 10 min, the supernatant containing the nuclear
protein was transferred into a prechilled microcentrifuge tube. The
extracts were stored at –80uC.
Western Blot
After being treated with diosgenin, PC-3 cells were washed
twice with PBS and treated with extraction buffer (50 mM Tris-Cl,
pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP-40, and 0.5%
deoxycholic acid). The cell extractions were collected and
centrifuged at 10,0006g for 10 min at 4uC, and the supernatants
were collected as cell lysates. The cell lysates were subjected to
SDS-PAGE, and transferred to nitrocellulose membranes (Milli-
pore, Bedford, MA). The membranes were blocked with 5% (w/v)
non-fat milk in PBS containing 0.1% Tween-20, and then blotted
with primary antibody. Subsequently, the membranes were
incubated with an appropriate secondary antibody (horseradish
peroxidase-conjugated goat anti-mouse or anti-rabbit IgG). The
immuno-detected proteins were then revealed by enhanced
chemiluminescence.
Statistical Analysis
Data were expressed as mean 6 standard deviation. Statistical
significance was analyzed by one-way ANOVA. If the significance
was observed, the Dunnett’s post-hoc test was used to determine
the difference between treatment groups and untreated group,
with values of p ,0.05 considered statistically significant.
Results
Cytotoxic Effect of Diosgenin in PC-3 Cells
We first elucidated the cytotoxic effect of diosgenin on prostate
cancer cells PC-3 (Fig. 1). We demonstrated that treated of
diosgenin at concentration below 20 mM for 24 or 48 hrs did not
affect viability of PC-3 cell significantly. Viability of PC-3 cell was
significantly decreased by diosgenin at 30 mM. The data indicated
that treatment with diosgenin at doses of no more than 20 mM for
24 and 48 hrs did not cause cytotoxicity of PC-3 cells.
Diosgenin Inhibits Migration in PC-3 Cells
Because a higher concentration of diosgenin was toxic, we
investigate the inhibitory effect of diosgenin on migration and
invasion of PC-3 cells using non-toxic doses. After incubation with
different concentrations of diosgenin for 24 hrs, diosgenin
suppressed migration of PC-3 cells to the denuded zone in a
dose-dependent manner (Fig. 2, A and B). These results revealed
that diosgenin inhibited the motility of PC-3 cells significantly.
Diosgenin Inhibits Invasion in PC-3 cells
To elucidate the inhibitory effect of diosgenin on the invasion of
PC-3 cells across the extracellular matrix, the cells that invaded
through the type-I collagen-coated polycarbonate filter in the
Boyden chamber were analyzed. The results showed that
diosgenin suppressed invasion of PC-3 cells across the type-I
collagen-coated filter in a dose-dependent manner. Treatment
with diosgenin of 10 and 20 mM inhibited 22% and 40% of cell
invasion, respectively (Fig. 3, A and B). The results indicated that
diosgenin markedly inhibited invasion of PC-3 cells.
Figure 5. Effect of diosgenin on PC-3 induced tube formation
of endothelial cell and VEGF expression. (A) HUVECs were seeded
onto Matrigel and incubated with conditioned medium from PC-3 cells
treated with diosgenin for 24 h. After 6 h, the enclosed networks of
complete tubes were photographed (1006 magnification). (B) The
tubular lengths of the cells were measured using Image J software. (C)
The mRNA expression of VEGF was determined and presented as mean
6 S.D. of three independent experiments. *p,0.05, **p,0.01,
compared with the untreated control.
doi:10.1371/journal.pone.0020164.g005
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and MMP-9 in PC-3 cells
Since the activation of MMPs is crucial for ECM degradation,
which is required for cell invasion, the effect of diosgenin on the
activation of MMPs was investigated. After PC-3 cells were treated
with various concentrations of diosgenin for 24 hrs in serum-free
medium, the conditioned medium was collected, concentrated and
assayed for MMP activity by gelatin zymography. The results
showed that MMP-9 and MMP-2 activities were markedly
reduced by 20 mM of diosgenin (Fig. 4A). We further demon-
strated that diosgenin suppressed the expression of MMP-9 and
MMP-2 mRNA and protein determined by RT-PCR and Western
Figure 6. Effects of diosgenin on phosphorylation of PI3K and Akt. PC-3 cells were treated with various doses of diosgenin for 24 h (A), or
20 mM of diosgenin for 3, 6, 12, 18 and 24 h (B). The phosphorylation of PI3K and Akt was determined by SDS-PAGE and Western blotting. b-actin was
used as a loading control.
doi:10.1371/journal.pone.0020164.g006
Figure 7. Effects of diosgenin on phosphorylation of ERK1/2, JNK1/2 and p38. PC-3 cells were treated with various doses of diosgenin for
24 h (A), or 20 mM of diosgenin for 3, 6, 12, 18 and 24 h (B). The phosphorylation of ERK1/2, JNK1/2 and p38 were determined by SDS-PAGE and
Western blotting. b-actin was used as a loading control.
doi:10.1371/journal.pone.0020164.g007
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both enzyme activities and expressions of MMP-9 and MMP-2
were inhibited by diosgenin.
Diosgenin Inhibits mRNA Expression of MMP-2, MMP-9,
MMP-7 and extracellular inducer of matrix
metalloproteinase (EMMPRIN) while Induces TIMP-2
Expression
In order to elucidate the effect of diosgenin on expression of
genes involved in ECM degradation, mRNA levels of MMP-2,
MMP-9, MMP-7, EMMPRIN, TIMP-1 and TIMP-2 were
analyzed by quantitative real-time PCR. The results demonstrated
that diosgenin inhibited the mRNA expression of MMP-2, MMP-
9, MMP-7 and EMMPRIN in a dose-dependent manner.
Diosgenin also elevated the expression of TIMP-2, which is
known to block the proteolytic potential of MMPs (Fig. 4D). The
results suggested that diosgenin might affect the expression of
genes involved in proteolytic activation.
Diosgenin inhibited PC-3 cell induced Human Umbilical
Vein Endothelial Cell (HUVEC) tube formation
Tube formation of endothelial cell is one of the crucial steps in
angiogenesis associated with the cancer progression and metas-
tasis. In order to examine the inhibitory effect of diosgenin on
PC-3 cell induced angiogenesis, we performed in vitro tube
formation of HUVEC by conditioned medium of PC-3 cells.
HUVEC grown on Matrigel was treated with the conditioned
media from PC-3 cells treated with diosgenin for 24 hrs, and tube
formation were evaluated. The results demonstrated conditioned
media of PC-3 cells induced tube formation of HUVEC, and
conditioned media from cells exposed to diosgenin suppressed
tube formation of HUVEC in a dose-dependent manner (Fig. 5,
A and B). The results suggested that diosgenin might suppress
PC-3 cell induced angiogenesis in vitro. Because PC-3 cells
induce angiogenesis through expressing angiogenic factors such
as VEGF, we evaluate whether diosgenin inhibits expression of
VEGF in PC-3 cells. Results demonstrated that mRNA
expression of VEGF in PC-3 cells was markedly decreased by
diosgenin in a dose-dependent manner (Fig. 5C). Our data
suggested that diosgenin inhibit PC-3 cell induced angiogenesis
by suppressing VEGF expression.
Diosgenin Inhibits phosphorylation of PI3K, Akt, ERK and
JNK
Several studies have indicated that the signaling proteins
including PI3K, Akt and MAPK members are involved in the
expression of MMPs and inducing metastasis [30,34,35]. The
effects of diosgenin on the phosphorylated status of PI3K, Akt,
ERK1/2, JNK1/2 and p38 in PC-3 cells were investigated. Data
demonstrated that diosgenin reduced the phosphorylation of PI3K
and Akt in a dose- and time-dependent manner (Fig. 6, A and B).
In addition, diosgenin suppressed the phosphorylation of ERK1/2
and JNK1/2 in a dose- and time-dependent manner, while it did
not alter the phosphorylation of p38 (Fig. 7, A and B).
To further investigate whether the inhibition of cell invasion
and MMP-2/9 expression were through inhibition of the ERK1/
2, JNK1/2 and PI3K signaling pathways, PC-3 cells were treated
with a PI3K inhibitor (LY294002; 20 mM), ERK inhibitor
(U0126; 20 mM) and JNK inhibitor (SP600125; 20 mM) for 24
hrs. Results showed that treatment of LY294002, U0126 and
SP600125 reduced cell invasion and MMP-2/9 expression
significantly (Fig. 8, A and B), suggesting that the inhibition of
cell invasion and MMP-2/9 expression by diosgenin could partly
occur through suppressing PI3K, ERK and JNK pathways.
Diosgenin Downregulates the Nuclear Content of NF-kB
in PC-3 Cells
To investigate the inhibitory effect of diosgenin on the activity of
NF-kB, the amount of IkBa in the cytosolic extracts and NF-kBi n
the cell nuclear extracts were measured by Western blotting. Data
revealed that diosgenin-treated PC-3 cells demonstrated an
increase in the cytosolic protein level of IkBa and a decrease in
the nuclear protein level of NF-kB (Fig. 9). The results implicated
that diosgenin significantly inhibited NF-kB activity.
Figure 8. Effect of PI3K inhibitor (LY294002), ERK inhibitor
(U0126) and JNK inhibitor (SP600125) on cell invasion and
MMP-2/9 expression of PC-3 cells. (A) Cells were treated with
LY294002, U0126 and SP600125 for 24 h and the cell invasive abilities
were performed by Boyden chamber invasion assay. (B) The expression
of MMP-2, -9 mRNA were determined and expressed as mean 6 S.D. of
three independent experiments. **p,0.01, ***p,0.001, compared with
the untreated control.
doi:10.1371/journal.pone.0020164.g008
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Diosgenin has been shown to possess anti-carcinogenic
potentials, such as inhibiting cell growth and inducing apoptosis
of various cancer cell lines [5,6,7,8,9,10]. In the present study, we
provided evidences that diosgenin was able to inhibit metastasis in
vitro, such as migration and invasion in human prostate cancer PC-
3 cells, suggesting that diosgenin might possess anti-metastatic
potential.
We demonstrated that diosgenin suppressed proliferation of PC-
3 cells significantly at the concentration of 30 mM. When PC-3
cells were treated with diosgenin at non-toxic doses (below
20 mM), migration and invasion were inhibited. These results
implied that the inhibitory effects of diosgenin on PC-3 cell
migration and invasion were not due to its cytotoxic effect.
Cancer metastasis requires migration of cancer cells. During cell
migration, pericellular proteolysis of ECM is important for cell
protrusion. The proteolytic degradation of ECM mediated by
extracellular proteases, such as MMPs, is required for prostate
cancer cell migration and invasion. Among them, MMP-2, MMP-
9 and MMP-7 play a critical role in prostate cancer progression.
Expression of MMP-2 and MMP-9 are associated with prostate
cancer progression [42,43]. Inhibition of MMP-2 and MMP-9
expression suppress the metastatic potential of prostate cancer
[32,44]. MMP-7 possesses proteolytic activity against a variety of
ECM substrates, including collagens, proteoglycans, elastin,
laminin, fibronectin, and casein. MMP-7 is also produced by
several malignant tumor cells including prostate, gastric, head and
neck, lung, hepatocellular, and colorectal carcinomas [45,46].
Overexpression MMP-7 promotes invasion of prostate cancer cells
[47]. In addition, EMMPRIN is able to regulate MMPs and be
involved in the invasion and metastasis processes of prostate
cancer cells [27]. Inhibition of EMMPRIN expression reduces
tumor cell invasion in human prostate cancer cell [48]. TIMPs, the
regulator of MMPs, are also involved in tumor progression,
invasion, metastasis and angiogenesis [49,50]. In the present study,
we showed that diosgenin inhibited migration and invasion of PC-
3 cells. Treatment with diosgenin of 10 and 20 mM for 24 hrs
diminished the activities and expression of MMP-2 and MMP-9
significantly. Diosgenin also inhibited mRNA expression of MMP-
7 and EMMPRIN in PC-3 cells. Besides, the expression of TIMP-
2 was increased by diosgenin. These results suggested that the
inhibition of MMP-2/9/7- and EMMPRIN-mediated enzymati-
cally degradative process and induction of TIMP-2 expression
might be attributed to the anti-invasive effect of diosgenin. The
inhibitory effect of diosgenin on MMPs may be, at least in part,
responsible for its anti-metastatic potential.
Angiogenesis, a critical step in tumor growth and metastasis, is
regulated by a variety of angiogenic factors, such as VEGF [51]. In
the present study, our data demonstrated that diosgenin inhibited
tube formation of endothelial cell, which is one of the first step in
angiogenesis. We further indicated that this inhibitory effect of
diosgenin could be mediated by the suppression of expression of
VEGF from prostate PC-3 cells. In agreement with our
observation, recent studies revealed that inhibition of tube
formation of endothelial cell through the suppression of VEGF
expression from a variety of cancer cells [44,52,53]. Therefore, we
suggested that diosgenin inhibited VEGF expression within PC-3
cells and subsequently resulted in the suppression of tumor
angiogenesis.
MMP activity is regulated by its gene expression and proenzyme
activation. Numerous reports have demonstrated that MMP-2 and
MMP-9 expression are critically mediated by MAPK members
and the PI3K/Akt pathway [34,36,37]. MAPK and PI3K/Akt
pathways also play an important role in tumor development and
progression [30,34,54]. Therefore, we examined the effect of
diosgenin on the activities of MAPK and PI3K/Akt signaling
pathways. The results demonstrated that treatment with diosgenin
inhibited ERK, JNK, PI3K and Akt phosphorylation significantly,
suggesting that the signaling pathways mediated by ERK, JNK
and PI3K/Akt were suppressed by diosgenin. In addition, we
showed that inhibitors of ERK, JNK and PI3K suppressed cell
invasion and MMP-2/9 mRNA expression of PC-3 cells
significantly. Therefore, we suggested that diosgenin inhibited
invasion of PC-3 cells might partly through suppressing ERK,
JNK and PI3K pathways. ERK, JNK and PI3K/Akt pathways
may be the potential targets for suppressing prostate cancer
metastasis.
Recent studies have demonstrated that inhibition of NF-kB
activity could suppress metastasis [31,33]. In the present study, we
demonstrated that diosgenin elevated IkBa protein level in the
cytoplasm and abolished NF-kB protein level in the nucleus,
suggesting that diosgenin suppressed the activity of NF-kB. Hence,
Figure 9. Effects of diosgenin on NF-kB activation. PC-3 cells were treated with various doses of diosgenin for 24 h. (A) The cytosolic and
nuclear extracts were prepared and analyzed for IkBa degradation and NF-kB p65 translocation. b-actin and C23 were used as a cytosolic and nuclear
protein loading control, respectively. (B) Determined levels of IkBa and NF-kB were quantified by densitometric analysis. The densitometric results
were expressed as mean 6 S.D. of three independent experiments. *p,0.05, **p,0.01, ***p,0.001, compared with the untreated control.
doi:10.1371/journal.pone.0020164.g009
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anti-metastatic mechanisms of diosgenin.
While we suggested diosgenin could inhibit PC-3 cell migration
and invasion through suppressing ERK, JNK, PI3K as well as NF-
kB pathways, whether the effect of diosgenin on expression of
MMP-2/9/7, TIMP-2, EMMPRIN and VEGF were mediated by
these pathways was not confirmed. Therefore, using RNAi
technique that specifically knockdown the expression of ERK,
JNK and PI3K to investigating the role of these signaling pathways
on expression of MMP-2/9/7, TIMP-2, EMMPRIN and VEGF
as well as cell invasion will be carried out in future.
In the present study, we demonstrated the inhibitory effect of
diosgenin on proliferation, migration and invasion of human
prostate cancer PC-3 cell. We also observed that diosgenin
suppressed proliferation and invasion of human lung carcinoma
A549 cell (unpublished data). Thus, diosgenin may have potential
for anti-metastatic therapy. Diosgenin is considered safe since it
does not manifest systemic toxicity, genotoxicity and estrogenic
activity [55]. Diosgenin is thought to be neither synthesized nor
metabolically converted into steroid by-products in the mamma-
lian body [1]. However, diosgenin is one of the aglycone of
steroidal saponins which may cause hemolysis after intravenous
administration and be quickly hydrolyzed after oral administration
[56]. This elicits the question that within a clinical perspective the
use of diosgenin could be compromised. Therefore, investigating
the therapeutic potential and pharmacodynamic property of
diosgenin in vivo is imperative. The animal study for investigating
the effect of diosgenin on prostate cancer metastasis will be
implemented in future.
In conclusion, we attributed the decrease in expression and
activity of MMP-2/9 by diosgenin to the inhibition of the ERK,
JNK and PI3K/Akt signaling pathways as well as NF-kB activity,
and such suppressive effect might contribute to the inhibition of
migration and invasion in human prostate cell PC-3 by diosgenin.
These findings reveal a new therapeutic potential for diosgenin on
anti-metastatic therapy.
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